Q3 EPS Forecast for Nurix Therapeutics Raised by Analyst

Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) - Research analysts at HC Wainwright lifted their Q3 2025 earnings per share estimates for shares of Nurix Therapeutics in a note issued to investors on Monday, July 14th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings per share of ($0.68) for the quarter, up from their prior estimate of ($0.76). HC Wainwright currently has a "Buy" rating and a $34.00 target price on the stock. The consensus estimate for Nurix Therapeutics' current full-year earnings is ($2.99) per share. HC Wainwright also issued estimates for Nurix Therapeutics' Q4 2025 earnings at ($0.89) EPS, FY2025 earnings at ($2.76) EPS, Q1 2026 earnings at ($0.91) EPS, Q2 2026 earnings at ($0.94) EPS, Q3 2026 earnings at ($0.97) EPS, Q4 2026 earnings at ($0.91) EPS and FY2026 earnings at ($3.73) EPS.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its earnings results on Wednesday, July 9th. The company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.79) by $0.27. The company had revenue of $44,056 billion during the quarter, compared to the consensus estimate of $16.26 million. Nurix Therapeutics had a negative net margin of 234.57% and a negative return on equity of 45.26%.

A number of other analysts have also issued reports on NRIX. Needham & Company LLC reaffirmed a "buy" rating and issued a $27.00 price target on shares of Nurix Therapeutics in a research note on Tuesday, April 29th. Wells Fargo & Company lowered their target price on shares of Nurix Therapeutics from $32.00 to $25.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 9th. UBS Group cut their target price on Nurix Therapeutics from $30.00 to $26.00 and set a "buy" rating on the stock in a research report on Thursday, July 10th. Wall Street Zen upgraded shares of Nurix Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, June 21st. Finally, Stifel Nicolaus dropped their price target on Nurix Therapeutics from $36.00 to $35.00 and set a "buy" rating on the stock in a research report on Wednesday, April 9th. Four equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to data from MarketBeat, Nurix Therapeutics has an average rating of "Moderate Buy" and an average target price of $29.31.

Nurix Therapeutics Stock Performance

Shares of NASDAQ NRIX traded down $0.88 during mid-day trading on Wednesday, hitting $11.21. The stock had a trading volume of 782,724 shares, compared to its average volume of 848,799. The company has a 50 day moving average of $11.47 and a two-hundred day moving average of $13.60. Nurix Therapeutics has a twelve month low of $8.18 and a twelve month high of $29.56. The firm has a market cap of $857.00 million, a PE ratio of -4.30 and a beta of 2.15.

Institutional Trading of Nurix Therapeutics

A number of hedge funds have recently modified their holdings of NRIX. Jump Financial LLC purchased a new stake in shares of Nurix Therapeutics in the 4th quarter valued at approximately $1,406,000. Affinity Asset Advisors LLC grew its position in shares of Nurix Therapeutics by 9.3% during the fourth quarter. Affinity Asset Advisors LLC now owns 940,083 shares of the company's stock worth $17,711,000 after buying an additional 79,684 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Nurix Therapeutics in the fourth quarter valued at approximately $1,026,000. RA Capital Management L.P. purchased a new position in Nurix Therapeutics in the fourth quarter worth approximately $25,120,000. Finally, Norges Bank acquired a new position in Nurix Therapeutics during the 4th quarter worth approximately $6,006,000.

Insiders Place Their Bets

In other news, CFO Houte Hans Van sold 6,198 shares of the company's stock in a transaction on Friday, May 2nd. The stock was sold at an average price of $11.33, for a total value of $70,223.34. Following the completion of the sale, the chief financial officer directly owned 33,724 shares in the company, valued at $382,092.92. This represents a 15.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Gwenn Hansen sold 3,377 shares of Nurix Therapeutics stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $11.50, for a total value of $38,835.50. Following the sale, the insider directly owned 61,516 shares in the company, valued at $707,434. This trade represents a 5.20% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 12,013 shares of company stock worth $137,096. Insiders own 7.40% of the company's stock.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.